These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24812153)

  • 1. A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats.
    Zhang J; Ye L; Wang W; Du G; Yu X; Zhu X; Dong Q; Cen X; Guan X; Fu F; Tian J
    Hum Exp Toxicol; 2015 Feb; 34(2):205-23. PubMed ID: 24812153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs.
    Tian J; Wang W; Ye L; Cen X; Guan X; Zhang J; Yu P; Du G; Liu W; Li Y
    Hum Exp Toxicol; 2014 May; 33(5):473-87. PubMed ID: 23925946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process.
    An T; Choi J; Kim A; Lee JH; Nam Y; Park J; Sun Bk; Suh H; Kim CJ; Hwang SJ
    Int J Pharm; 2016 Apr; 503(1-2):8-15. PubMed ID: 26899975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats.
    Ye L; Guan X; Tian J; Zhang J; Du G; Yu X; Yu P; Cen X; Liu W; Li Y
    Food Chem Toxicol; 2013 Jun; 56():81-92. PubMed ID: 23454207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
    Tian J; Du G; Ye L; Yu X; Zhang J; Wang H; Yu P; Fu F; Liu W; Li Y; Cen X; Guan X
    Food Chem Toxicol; 2013 Feb; 52():143-52. PubMed ID: 23165154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsphere delivery of Risperidone as an alternative to combination therapy.
    D'Souza S; Faraj J; DeLuca P
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
    Gomeni R; Heidbreder C; Fudala PJ; Nasser AF
    J Clin Pharmacol; 2013 Oct; 53(10):1010-9. PubMed ID: 23868656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
    Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX
    Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical review of a long-acting, injectable formulation of risperidone.
    Knox ED; Stimmel GL
    Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
    Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
    Ereshefsky L; Mascarenas CA
    J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The new antipsychotic preparation Rispolept (risperidone)].
    Iakovlev VA
    Voen Med Zh; 1999 Nov; 320(11):43-5. PubMed ID: 10650767
    [No Abstract]   [Full Text] [Related]  

  • 15. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.
    Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
    J Clin Pharmacol; 2015 Jan; 55(1):93-103. PubMed ID: 25043337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience and management considerations with long-acting risperidone.
    Parellada E
    Curr Med Res Opin; 2006 Feb; 22(2):241-55. PubMed ID: 16466596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics.
    de Waal EJ; Desmidt M; Korte S; Niehoff M; Chase K; Arrowsmith W; Lampo A
    J Appl Toxicol; 2014 Sep; 34(9):974-92. PubMed ID: 24105799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
    Duncan EJ; Woolson SL; Hamer RM
    Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.
    Thyssen A; Rusch S; Herben V; Quiroz J; Mannaert E
    J Clin Pharmacol; 2010 Sep; 50(9):1011-21. PubMed ID: 20097933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
    Peng PW; Huang MC; Tsai CJ; Pan CH; Chen CC; Chiu CC
    J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.